Form 4: Alnylam Pharmaceuticals CSO Kevin Fitzgerald Sells Shares to Cover Tax Obligations
SEC Form 4
Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, sold shares of common stock on February 28, 2025, to cover tax obligations arising from the vesting of restricted stock units.
Summary
- On February 28, 2025, Kevin Fitzgerald, the CSO & EVP, Head of Research at Alnylam Pharmaceuticals, sold shares of the company's common stock.
- The sales were executed to cover minimum statutory tax withholding obligations due upon the vesting and settlement of restricted stock units granted on February 27, 2023.
- A total of 548 shares were sold at varying prices ranging from $236.51 to $244.32.
- Following the transactions, Fitzgerald directly owns 12,385 shares of Alnylam common stock and indirectly owns 537 shares through a managed account.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so the sentiment is neutral.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This filing provides transparency into such transactions.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a routine transaction to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| February 27, 2023 | Date of grant for the restricted stock units that triggered the tax obligations. |
| February 28, 2025 | Date of the stock sale transactions. |
| March 03, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.